Search

Displaying results 2661 - 2670 of 10000 in total
  1. Drug

    Fluorouracil

    go.drugbank.com/drugs/DB00544
    ApprovedInvestigational

    It interferes with DNA synthesis by blocking the thymidylate synthetase conversion of deoxyuridylic acid to thymidylic acid.

  2. Drug

    Betibeglogene autotemcel

    go.drugbank.com/drugs/DB16900
    ApprovedInvestigational

    [L42940] β-thalassemia is a condition caused by mutations in the β-globin gene (HBB) that leads to a significant decrease in the production of β-globin. … [A251770,A251785] Betibeglogene autotemcel was approved by the FDA in August 2022 and is the first ex-vivo lentiviral vector gene therapy available in the U.S. for the treatment of people with β-thalassemia

  3. Drug

    Anastrozole

    go.drugbank.com/drugs/DB01217
    ApprovedInvestigational

    as compared to earlier estrogen receptor modulators such as [tamoxifen]. … Anastrozole is a non-steroidal aromatase inhibitor (AI), similar to [letrozole], used to decrease circulating estrogen levels in the treatment of postmenopausal women with estrogen-responsive breast cancer

  4. Drug

    Propafenone

    go.drugbank.com/drugs/DB01182
    ApprovedInvestigational

    The drug is generally well tolerated.

  5. Drug

    Enoxacin

    go.drugbank.com/drugs/DB00467
    Approved

    A broad-spectrum 6-fluoronaphthyridinone antibacterial agent (fluoroquinolones) structurally related to nalidixic acid.

  6. Drug

    Potassium cation

    go.drugbank.com/drugs/DB01345
    Approved

    The balance between potassium and sodium is maintained by ion pumps in the cell membrane. … The concentration differences of these charged particles causes a difference in electric potential between the inside and outside of cells, known as the membrane potential.

  7. Drug

    Denosumab

    go.drugbank.com/drugs/DB06643
    ApprovedInvestigational

    Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption via inhibiting RANK-mediated activation of … It is the first and currently the only RANKL inhibitor approved to prevent osteoclast-mediated bone loss.

  8. Drug

    Mecasermin

    go.drugbank.com/drugs/DB01277
    ApprovedInvestigational

    The amino acid sequence of the product is identical to that of endogenous human IGF-1. … The rhIGF-1 protein is synthesized in bacteria (E. coli) that have been modified by the addition of the gene for human IGF-1.

  9. Drug

    Methscopolamine bromide

    go.drugbank.com/drugs/DB00462
    Approved

    A muscarinic antagonist used to study binding characteristics of muscarinic cholinergic receptors.

  10. Drug

    Cimetidine

    go.drugbank.com/drugs/DB00501
    ApprovedInvestigational

    It also blocks the activity of cytochrome P-450 which might explain proposals for use in neoadjuvant therapy. … A histamine congener, it competitively inhibits histamine binding to histamine H2 receptors. Cimetidine has a range of pharmacological actions.